Dr Claire Lansdall
Herchel-Smith Building, Cambridge Biomedical Campus
My research focuses on the cognitive, behavioural and neurobiological changes associated with frontotemporal dementia, progressive supranuclear palsy and corticobasal syndrome. I am particularly interested in understanding the mechanisms underlying apathy and impulsivity, which frequently coexist and cause substantial patient morbidity and carer distress, but remain poorly treated. My work employs a range of clinical, neuropsychiatric and behavioural assessments, MRI brain imaging and pharmacological intervention.
Magnetic resonance imaging (MRI)
No collaborators listed
Associated News Items
Lansdall CJ, Coyle-Gilchrist ITS, Dick KM, Vázquez Rodríguez P, Wehmann E, Wilcox A, Dick KM, Robbins TW, Rowe JR. (2017), “Apathy and impulsivity in frontotemporal lobar degeneration syndromes. ” Brain 140(6): 1792-1807
Bevan-Jones W, Jones S, Passamonti L, Lansdall CJ, Ghosh B, Rittman T, Coyle-Gilchrist I, Allinson K, Dawson C, Rowe JB. (in press), “Progressive supranuclear palsy: structural correlates of survival.” Movement Disorders
Brown J, Lansdall CJ, Wiggins J, Dawson K, Hunter K, Parker R, Rowe JB. (2017), “ The Test Your Memory for Mild Cognitive Impairment (TYM-MCI) test. A short cognitive test to aid the diagnosis of amnestic MCI and mild Alzheimer’s disease.” JNNP
Lansdall CJ, Coyle-Gilchrist ITS, Jones PS, Vázquez Rodríguez P, Wehmann E, Wilcox A, Dick KM, Robbins TW, Rowe JR. (in press), “White matter change with apathy and impulsivity in frontotemporal lobar degeneration syndromes.” Neurology
Passamonti L., Lansdall CJ., Rowe JB. (2017), “The neuroanatomical and neurochemical basis of apathy and impulsivity in frontotemporal lobar degeneration” Current Opinion in Behavioral Sciences 22; 14–20
Coyle-gilchrist ITS, Dick KM, Vázquez Rodríguez P, Wehmann E, Wilcox A, Lansdall CJ, Dawson KE, Wiggins JW, Mead S, Brayne C, Rowe JR. (2016), “Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes.” Neurology 86: 1–8.
Lansdall CJ. (2014), “An effective treatment for Alzheimer’s disease must consider both amyloid and tau.” Biosci. Horizons 7: 1-11